InspireMD Q2 Revenue Flat; International Sales Rise 21% As Company Advances CGuard U.S. Relaunch
InspireMD (NSPR) reported Q2 2026 revenue of $1.8M, flat year over year, as international sales rose 21% to $2.1M but U.S. revenue fell to -$0.4M due to a voluntary recall and $0.7M in customer credits. Net loss was $14.3M ($0.17/share). The company is redesigning CGuard Prime 135 cm for FDA submission and expects U.S. relaunch pending approval.
How this was made
The 30-second read
Why it matters
Q2 results show flat revenue with a clear U.S. drag from recall-related credits and inventory impairment, while management outlines design changes, validation testing, and an FDA submission expected before year-end. Clinical enrollment has started for CGUARDIANS III, and CGUARDIANS II reports 100% acute device success through 30 days.
Market read
Traders can frame the stock around two competing forces: recall-driven near-term financial deterioration versus a defined relaunch and regulatory/clinical catalyst path.
What to watch
Gross loss includes a large inventory impairment and recall credits, so investors may over-penalize the underlying operating trajectory versus what normalized margins could look like post-relaunch.
Background
InspireMD is developing the CGuard Prime carotid stent system for stroke prevention and is working through U.S. relaunch steps after technical challenges and a voluntary recall.
Ticker impact
InspireMD reported Q2 revenue flat at $1.8M, with international up 21% but U.S. revenue hit by a voluntary CGuard Prime recall and $0.7M in customer credits.
Choppy to downside-biased until FDA submission/decisions and validation testing de-risk the relaunch; upside possible on any positive regulatory or trial readouts.
The article discloses concrete financial impacts from the recall (credits, inventory impairment) plus specific operational milestones (design changes, FDA submission before year-end, patient enrollment start, and expected FDA decisions later this year).
Market effects
Highlights execution risk and regulatory dependency for carotid stent platforms, with recall-driven financial noise but continued clinical progress.
U.S. commercialization remains impaired while international demand is growing, implying shifting regional revenue mix.
International growth may partially offset U.S. setbacks, but FDA outcomes remain the key global valuation driver for this device platform.
Counterpoint
The international growth and ongoing trial success metrics could outweigh the recall noise if the redesigned delivery system validates and FDA engagement is smooth.
Key entities
- companyInspireMD, Inc.
NSPR, medical device company developing the CGuard Prime carotid stent system; reported Q2 results, recall impacts, and relaunch/clinical updates.
- productCGuard Prime 135 cm delivery system
Delivery system redesign undergoing validation and performance testing ahead of an FDA submission expected before year-end.
- clinical_programCGUARDIANS III pivotal trial
Evaluates SwitchGuard neuroprotection system with the CGuard Prime 80 cm stent platform; patient enrollment has begun.
- clinical_programCGUARDIANS II trial
Reports 100% acute device success with no deaths, strokes, MI, or stent thrombosis through 30 days.
- regulatory_eventFDA decisions later this year
Expected FDA decisions regarding CGuard Prime 80 cm implant for TCAR and the original CGuard platform for traditional carotid stenting.
